These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1662290)

  • 41. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
    Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
    Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic study of a new quinolone, DW-116.
    Lee DK
    Drugs; 1995; 49 Suppl 2():323-5. PubMed ID: 8549349
    [No Abstract]   [Full Text] [Related]  

  • 43. [Experimental and clinical studies of temafloxacin in the field of obstetrics and gynecology].
    Matsuda S; Shimizu T; Cho N; Okada H
    Jpn J Antibiot; 1993 Jun; 46(6):492-504. PubMed ID: 8395608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New quinolones].
    Matsumoto F; Morita M; Sato Y
    Nihon Rinsho; 1990 Oct; 48(10):2205-11. PubMed ID: 2177796
    [No Abstract]   [Full Text] [Related]  

  • 45. [Significant role of newer quinolone antimicrobials in respiratory tract infection: focused on sparfloxacin].
    Jpn J Antibiot; 1994 Oct; 47(10):1241-58. PubMed ID: 7807686
    [No Abstract]   [Full Text] [Related]  

  • 46. Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians?
    Jones RN
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):177-9. PubMed ID: 1315235
    [No Abstract]   [Full Text] [Related]  

  • 47. [Comparative pharmacokinetics of lomefloxacin and other fluoroquinolones].
    Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):46-52. PubMed ID: 9825111
    [No Abstract]   [Full Text] [Related]  

  • 48. [Theoretical research for therapy of infection].
    Shimizu K
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Aug; 43(8):815-23. PubMed ID: 1655924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Bactericidal action of lomefloxacin a new pyridonecarboxylic acid derivative].
    Koikeda S; Okabe H; Shibata H; Hase T; Nakanishi N; Okezaki E; Kato H; Masamune Y
    Jpn J Antibiot; 1989 Jan; 42(1):193-9. PubMed ID: 2468799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lomefloxacin sensitivities.
    Smith JM; Hashmi ZS
    N Z Med J; 1989 Jul; 102(872):391. PubMed ID: 2797570
    [No Abstract]   [Full Text] [Related]  

  • 51. [Difluoroquinolone lomefloxacin (Maxaquin): its role among fluoroquinolones, possibilities and prospectives].
    Padeĭskaia EN
    Antibiot Khimioter; 1998; 43(10):4-9. PubMed ID: 9825101
    [No Abstract]   [Full Text] [Related]  

  • 52. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New fluoroquinolones and treatment of acute sinusitis].
    Gehanno P; Trémolières F
    Presse Med; 1999 Sep; 28(25):1365. PubMed ID: 10506868
    [No Abstract]   [Full Text] [Related]  

  • 54. [New antimicrobial agent series XXXIII: Flomoxef].
    Shimizu K
    Jpn J Antibiot; 1988 Dec; 41(12):1809-21. PubMed ID: 3074180
    [No Abstract]   [Full Text] [Related]  

  • 55. Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.
    Jones RN; Kehrberg EN; Erwin ME
    Drugs; 1995; 49 Suppl 2():179-81. PubMed ID: 8549295
    [No Abstract]   [Full Text] [Related]  

  • 56. The synthesis of fluorine-18 lomefloxacin and its preliminary use in human studies.
    Tewson TJ; Yang D; Wong G; Macy D; DeJesus OJ; Nickles RJ; Perlman SB; Taylor M; Frank P
    Nucl Med Biol; 1996 Aug; 23(6):767-72. PubMed ID: 8940719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Major advances in antibacterial quinolone therapy.
    Neu HC
    Adv Pharmacol; 1994; 29A():227-62. PubMed ID: 7826861
    [No Abstract]   [Full Text] [Related]  

  • 58. [Current antimicrobial agent series III: Norfloxacin].
    Ueda Y; Matsumoto F
    Jpn J Antibiot; 1988 Jul; 41(7):782-96. PubMed ID: 3050183
    [No Abstract]   [Full Text] [Related]  

  • 59. European Study Group on Antibiotic Breakpoints. Breakpoint determination: sparfloxacin.
    Phillips I; Acar J; Baquero F; Bergan T; Degener J; Forsgren A; Schito GC; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1994 Mar; 13(3):283-4. PubMed ID: 8050449
    [No Abstract]   [Full Text] [Related]  

  • 60. [New antimicrobial agents series XXXIV: isepamicin].
    Katsu M; Saito A
    Jpn J Antibiot; 1989 Mar; 42(3):543-66. PubMed ID: 2664247
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.